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Eﬀects of the ethanol extract of Fructus Schisandrae (EtFSC) on serum and liver lipid contents were investigated in mice fed
with high fat/cholesterol (HFC) diet for 8 or 15 days. The induction of hypercholesterolemia by HFC diet caused signiﬁcant
increases in serum and hepatic total cholesterol (TC) levels (up to 62% and 165%, resp.) and hepatic triglyceride (TG) levels
(up to 528%) in mice. EtFSC treatment (1 or 5g/kg/day for 7 days; from Day 1 to 7 or from Day 8 to 14, i.g.) signiﬁcantly
decreased the hepatic TG level (down to 35%) and slightly increased the hepatic index (by 8%) in hypercholesterolemic mice.
Whereas fenoﬁbrate treatment (0.1g/kg/day for 7 days, i.g.) signiﬁcantly lowered the hepatic TG level (by 61%), it elevated
the hepatic index (by 77%) in hypercholesterolemic mice. Acute toxicity test showed that EtFSC was relatively non-toxic, with
an LD50 value of 35.63 ± 6.46g/kg in mice. The results indicate that EtFSC treatment can invariably decrease hepatic TG in
hypercholesterolemic mice, as assessed by both preventive and therapeutic protocols, suggesting its potential use for fatty liver
treatment.
1.Introduction
Fatty liver, characterized by the buildup of fat in liver cells,
is prevalent in modern societies. In USA as well as European
and Asian countries, the incidence of fatty liver is 15–20%
of the general population, and it is much higher in obese
individuals [1–4]. Although fat present in the liver usually
causes no damage by itself, in some situations abnormal
accumulation of lipids in the liver may interfere with normal
liverfunctionsandcauseshepatocyteinjury,hepatocirrhosis,
and hepatocellular carcinoma [5–7]. It is therefore of great
pharmacological interest to develop drugs that may prevent
or ameliorate liver steatosis. Fatty liver is also associated with
diabetes mellitus, tuberculosis, malnutrition, excess vitamin
A in the body, or the uses of certain drugs, and it occurs even
as a complication of pregnancy [8]. Severe fatty liver is more
often due to improper diet, alcohol excess and obesity. At
present, fatty liver is a commonly occurring health problem.
Fructus Schisandrae (FSC), the fruit of Schisandra chi-
nensis, is a traditional Chinese herb (Wu-Wei-Zi) originally
recorded in Shen Nong Ben Cao Jing (an over 2000 years old
Herbal Pharmacopoeia in China). Its active components and
related synthetic derivatives, such as schisandrin B, bifendate
and bicyclol, have been shown to reduce the hepatotoxicity
produced by chemicals in animals and to treat patients
with chronic viral hepatitis in clinic conditions [9–14].
The hepatic lipid-lowering eﬀect of bicyclol treatment on
alcohol-induced fatty liver has also been demonstrated in
mice [15]. Our previous studies have shown that the treat-
ment with bifendate, bicyclol or schisandrin B antagonized
hepatic steatosis in mice with hypercholesterolemia caused
by feeding a cholesterol/bile salt or high-fat diet [16–20]. In
the present study, we endeavored to investigate the eﬀects
of the ethanol extract of FSC (EtFSC) on serum/hepatic
triglyceride (TG) and total cholesterol (TC) levels in hyperc-
holesterolemic mice produced by high fat/cholesterol (HFC)2 Evidence-Based Complementary and Alternative Medicine
diet,withanobjectiveofestablishingapharmacologicalbasis
for its potential application in the treatment of fatty liver.
2. Methods
2.1. Preparation of Herbal Extract. FSC was obtained from
the Anguo Chinese material medica market and authenti-
cated by Dr H. Dong. FSC was ground into small pieces
and extracted twice with ﬁve volumes of 80% (v/v, in
H2O) ethanol under reﬂux. The extracts were combined
and ﬁltered through a paper ﬁlter. The pooled extract was
concentrated by rota-evaporation under reduced pressure
until the removal of all ethanol. EtFSC was reconstituted in
w a t e r( w i t h2go fr a wh e r bi n1m lo fe x t r a c t )a n ds t o r e da t
4◦C until use.
2.2. Chemicals and Reagents. Cholesterol (certiﬁcate no.
041103) was obtained from Beijing Chemical Reagent
Co. (Beijing, China). Fenoﬁbrate (certiﬁcate no. 0405030)
was bought from Beijing Yongkang Medical Ltd. (Beijing,
China). Sodium carboxymethylcellulose (CMC, certiﬁcate
no. 971230) was obtained from Beijing Xudong Chemical
Plant(Beijing,China).AssaykitsforTCandTGwerebought
from Zhongsheng Beikong Bio-technology and Science Inc.
(Beijing, China).
2.3. Animal Treatment. Male ICR mice (Grade II, certiﬁcate
No. SCXK(jing) 2002–0003), weighing 18–20g, were sup-
plied by Vital River Lab Animal Co. Ltd (Beijing, China). All
animals were maintained on a 12h (light on 7:00–19:00h)
light-dark cycle at 20-21◦C, with a relative humidity of 50–
55%. They were allowed free access to water and food.
Experiments were performed when the animals had grown
up to a body weight of 24–26g. Hypercholesterolemia was
induced by feeding high-fat diet (10% lard, w/w) containing
cholesterol (1%, w/w). Non-hypercholesterolemic (normal)
animals were given the normal diet. In the drug treatment
groups, EtFSC or fenoﬁbrate (suspended in 0.5% CMC)
was intragastrically administered at doses of 1–5 (based on
raw herb) or 0.1g/kg, respectively. The dosage of EtFSC
adopted for the present pharmacological investigation was
much higher than the recommended intake of FSC (1.5–5g
daily) for a human adult with an average body weight of
60kg.
The experimental design aimed to investigate the pre-
ventive and therapeutic eﬀects of EtFSC treatment on liver
steatosis. Mice were fed with HFC diet for 8 or 15 days.
EtFSC (1–5g/kg/day) or fenoﬁbrate (0.1g/kg/day) treatment
was performed for 7 days (from Day 1 to 7 (preventive) or
from Day 8 to 14 (therapeutic)). Drug-untreated animals
received the vehicle (0.5% CMC) at 10ml/kg. Animals were
sacriﬁced 24h after the last dosing with EtFSC or fenoﬁbrate.
Blood and liver tissue samples were obtained from ether-
anesthetized animals which had been fasted for 6h (from
6:00 to 12:00h), and they were subjected to biochemical
analyses. Hepatic index was estimated from the ratio of total
liver weight to body weight. Experimental protocols were
approved by the University Committee on Research Practice
in Beijing University of Chinese Medicine.
2.4. Determination of TotalCholesterol and TriglycerideLevels.
Serum samples were prepared by centrifuging the whole
blood obtained from the orbital vein for 8min at 2000×g.
The liver tissue sample was homogenized in 9 volumes of
0.9% (w/v) NaCl solution by two 10-s bursts of a tissue
disintegrator and the homogenate was then centrifuged at
2000g for 15min to obtain the supernatants. Aliquots of 10
and 40μl of the hepatic supernatants were used to determine
the TG and TC levels, respectively.
2.5. Statistical Analysis. Data were analyzed using Student’s
t-test and P<. 05 was considered signiﬁcant. Values are
expressed as means ± SEM for 10 mice per group.
3. Results
3.1. EtFSC/Fenoﬁbrate Treatment Changed Serum Triglyceride
and Total Cholesterol Level in Hypercholesterolemic Mice.
Feeding micewithHFCdiet for8dayssigniﬁcantlyincreased
serum TC and TG levels (by 62% and 29%, resp.), when
compared with animals fed with normal diet (Figure 1(a)).
EtFSC and fenoﬁbrate treatment (from Day 1 to 7) increased
serum TC levels (by 8% and 20%, resp.), when compared
with the drug-untreated hypercholesterolemic mice. The
fenoﬁbrate, but not EtFSC, treatment signiﬁcantly reduced
serum TG levels (by 45%) in hypercholesterolemic mice
(Figure 1(a)).
As shown in Figure 1(b), feeding mice with HFC diet for
15 days increased the serum TC levels (by 50%), but it did
not aﬀect the serum TG level. Both EtFSC and fenoﬁbrate
treatments (from Day 8 to 14) increased the serum TC level
(by 2–19%). In contrast, they decreased the serum TG level
(by 44% and 72%, resp.) in hypercholesterolemic mice.
3.2. EtFSC/Fenoﬁbrate Treatment Decreased Hepatic Triglyc-
eride and/or Total Cholesterol Level in Hypercholesterolemic
Mice. Feeding mice with HFC diet for 8 days signiﬁcantly
increased hepatic TC and TG levels (by 118% and 107%,
resp.), when compared with animals fed with normal diet.
EtFSC treatment (5g/kg/day × 7, from Day 1 to 7) signiﬁ-
cantlydecreasedhepaticTGlevels(by26%),whencompared
with the drug-untreated hypercholesterolemic mice. Hepatic
TC level was not aﬀected by EtFSC or fenoﬁbrate treatment
in mice fed with HFC diet (Figure 2(a)).
FeedingmicewithHFCdietfor15daysincreasedhepatic
TC (by 165%) and TG (by 528%) levels, when compared
with that of mice fed with normal diet. EtFSC treatment
(1 or 5g/kg/day × 7, from Day 8 to 14) produced dose-
dependent decreases in hepatic TG levels (by 25–35%), when
compared with the drug-untreated hypercholesterolemic
mice. Fenoﬁbrate signiﬁcantly decreased both hepatic TG
and TC levels (by 61% and 64%, resp.), when com-
pared with the drug-untreated hypercholesterolemic mice
(Figure 2(b)).
3.3. Eﬀects of EtFSC/Fenoﬁbrate Treatment on Liver Weight
in Hypercholesterolemic Mice. Figure 3 shows the EtFSC/
fenoﬁbrate-induced changes in hepatic index in HFCEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀects of EtFSC/fenoﬁbrate treatment on serum triglyceride and total cholesterol levels in mice fed with HFC for 8 days (a) or
15 days (b). EtFSC (1–5g/kg/day, i.g.) or fenoﬁbrate (0.1g/kg/day, i.g.) treatment was performed for 7 days (from Day 1 to 7 or from Day
8 to 14). Normal and drug-untreated hypercholesterolemic animals received the vehicle (0.5% CMC 10ml/kg/day, i.g.) only. Twenty-four
hours after the last dosing, serum triglyceride and total cholesterol levels were determined. Values given are the mean ± SEM of 10 mice
per group. ∗P<. 05, ∗∗P<. 01 and ∗∗∗P<. 001 versus the normal group; †P<. 05, ††P<. 01 and †††P<. 001 versus the drug-untreated
hypercholesterolemic group.
Table 1: Acute toxicity of EtFSC in mice.
Dose (g/kg) Number of animal Mortality rate (%)
19.6 10 10
28.0 10 30
40.0 10 40
57.0 10 100
Mice were divided into four groups of 10 animals in each and orally
administered with EtFSC at doses of 19.6–57g/kg. The mortality rate in
each group was determined within 24-h post-dosing. LD50 value (35.63 ±
6.46g/kg) was estimated by Bliss method.
diet-fed mice. The hepatic index was increased in hyper-
colesterolemic mice (up to 21%), when compared with the
normal diet-fed mice. EtFSC treatment increased the hepatic
index (by 8%) in 15-day HFC diet-fed mice (Figure 3b),
but it did not aﬀect the hepatic index in 8-day HFC diet-
fed mice (Figure 3a). Fenoﬁbrate signiﬁcantly elevated the
hepatic index (up to 77%) in both 8- and 15-day HFC
diet-fed mice, when compared with the drug-untreated
hypercholesterolemic mice (Figures 3aa n d3b).
3.4. Acute Toxicity of EtFSC. In the acute toxicity test, EtFSC
was administered intragastrically at increasing doses (19.6–
57g/kg) and the mortality rate was determined within 24h
post-dosing in mice. LD50 value of EtFSC was estimated to
be 35.63 ± 6.46g/kg, using the Bliss method (Table 1).
4. Discussion
Fatty liver is caused by sedentary lifestyle, diet enriched
with cholesterol and saturated fats, and medical conditions.
Lifestylecontributorsincludeobesity,deprivationofphysical
exercise, and excessive alcohol consumption [21]. In the
present study, feeding with HFC diet for 8 or 15 days
markedly increased serum TC, hepatic TG and TC levels in
mice, with the extent of elevation for hepatic TG being more
prominent. Serum TG level was slightly increased in mice fed
with HFC diet for 8 but not 15 days. The animal model used
in the present study therefore mimics the clinical condition
of fatty liver rather than hyperlipidemia. In most instances,
the treatment of fatty liver requires a proper control of the
underlying abnormal conditions, including high blood TG
level, diabetes, excessive alcohol intake and obesity [22]. At
present, orthodox medicine has no speciﬁc drug treatment
to reverse a condition of fatty liver. Moreover, most of the
synthetic lipid-lowering drugs can lead to various adverse
reactions, even though they can alleviate the condition of
hepaticsteatosis.Assuch,theWorldHealthOrganizationhas
adopted a policy in favor for development of herbal remedies
for the clinical management of hepatic steatosis.
The acute treatment with EtFSC increased the serum TG
level and at the same time, decreased hepatic TC level in
normalmice.Asexpected,thehypertriglyceridemicactionof
EtFSC is suppressed by the co-administration of fenoﬁbrate
(data not shown). Fenoﬁbrate, a broad-spectrum lipid-
lowering drug of the ﬁbrate class, inhibits the synthesis4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀects of EtFSC/fenoﬁbrate treatment on hepatic triglyc-
eride and total cholesterol levels in mice fed with HFC for 8 days
( a )o r1 5d a y s( b ) .E x p e r i m e n t a ld e t a i l sw e r ed e s c r i b e di nFigure 1.
Twenty-four hours after the last dosing, hepatic triglyceride and
total cholesterol levels were determined. Values given are the mean
± SEM of 10 mice per group. ∗∗P<. 01 and ∗∗∗P<. 001 versus the
normal group; †P<. 05 and †††P<. 001 versus the drug-untreated
hypercholesterolemic group.
o fc h o l e s t e r o la n dt r i g l y c e r i d e sa sw e l la se n h a n c e st h e i r
elimination [23, 24]. In the present study, it was found that
both fenoﬁbrate and EtFSC treatment for 7 days reduced the
serumTGlevelbutelevatedtheserumTClevelsinHFCdiet-
induced hypercholesterolemic mice. The blood TG lowering
eﬀectmayberelatedtothehighbloodTClevelsinHFCdiet-
fed mice. Possibly, hypercholesterolemia may facilitate the
utilization of or inhibit the synthesis of TG. The fenoﬁbrate-
or EtFSC-induced increase in serum TC levels may result
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Figure3:EﬀectsofEtFSC/fenoﬁbratetreatmentonhepaticindexin
hypercholesterolemic mice. Experimental details for insets (a) and
(b) were described in Figure 1. Hepatic index was estimated by the
ratio of the whole liver weight to body weight. Values given are the
mean ± SEM of 10 mice per group. ∗∗P<. 01 and ∗∗∗P<. 001
versus the normal group; †P<. 05 and †††P<. 001 versus the drug-
untreated hypercholesterolemic group.
from the secretion of hepatic TC into the blood stream.
While fenoﬁbrate did not reduce hepatic TC levels in mice
fed with HFC diet for 8 days, it lowered hepatic TC in mice
fed with HFC diet for 15 days. This observation may be due
to a higher content of hepatic TC in mice fed with HFC diet
for 15 days than those fed with HFC diet for 8 days.
It has been reported that the hypolipidemic action of
fenoﬁbrate is attributed to the stimulation of lipolysis and
the elimination of TG-rich particles from plasma through
activating lipoprotein lipase and reducing the production
of apolipoprotein C-III, as well as inducing enzymes for
catalyzing β-oxidation of fatty acid in mitochondria [25–27].
In addition, fenoﬁbrate also reduces intestinal cholesterol
absorption [28]. Therefore, the mechanism involved in
the reduction of hepatic TG level in hypercholesterolemic
mice by EtFSC treatment may also be due to its eﬀect
on the lipoprotein lipase, apolipoprotein C-III, β-oxidation,
or/and cholesterol absorption. The detail mechanism of
action remains to be elucidated. In our previous study, the
treatmentofschisandrinB,bifendate(syntheticintermediate
of schisandrin C) and bicyclol (synthetic dibenzocyclooc-
tadiene derivative) [16–20] produced a signiﬁcant hepa-
totrophic eﬀect, but EtFSC treatment only slightly increased
the hepatic index in hypercholesterolemic mice. The lesser
degree of liver hypertrophy caused by EtFSC than puriﬁed
active principles including schisandrin B, bifendate, and
bicyclol and fenoﬁbrate, and the relatively low toxicity might
make EtFSC a desirable candidate herbal preparation for the
treatment of fatty liver.
Peroxisomeproliferator-activatedreceptors(PPARs)play
important roles in the regulation of lipid metabolismEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Hypothetical action of EtFSC in lowering liver lipid
content through the intermedicacy of PPARs.
involved in inﬂammation, energy balance, atherosclerosis
and non-alcoholic fatty liver disease [29–31]. Fenoﬁbrate, an
agonist of PPARα, is a useful therapeutic option for patients
with dyslipidemias, particularly those associated with dia-
betes mellitus or coronary heart disease, and metabolic
syndrome [32, 33]. EtFSC may activate PPARs and thereby
suppress the lipid accumulation in the liver (Figure 4).
In conclusion, EtFSC treatment could prevent or ame-
liorate the degree of liver steatosis in hypercholesterolemic
mice. While fenoﬁbrate produced a more potent lipid-
lowering action than that of EtFSC, it caused a larger extent
of liver hypertrophy. Taken together with the relatively low
toxicity, EtFSC may be used clinically for the management of
fatty liver disease [34].
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